Shire has licensed the activin receptor type IIB (ActRIIB) class of molecules being developed for the potential treatment of Duchenne Muscular Dystrophy (DMD), from Acceleron Pharma, Inc. The collaboration will initially investigate ACE-031, Acceleron’s lead ActRIIB drug candidate currently in Phase II development. DMD is a fatal muscle disease with no current treatment. ACE-031 and other ActRIIB molecules have the potential to be used in other muscular and neuromuscular disorders with hig...